Biocon, Mylan NV launch Ogivri in US

03 Dec 2019 Evaluate

Biocon and Mylan NV have launched Ogivri (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab) in US. Ogivri is available in a 420 mg multi-dose vial and a 150 mg single-dose vial in order to provide patient dosing and treatment flexibility.

Ogivri was the first biosimilar trastuzumab approved by the US Food and Drug Administration (USFDA) and unanimously recommended by the USFDA Oncologic Drugs Advisory Committee (ODAC).

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

377.55 -1.50 (-0.40%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×